Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)
Identifieur interne : 00A246 ( Main/Exploration ); précédent : 00A245; suivant : 00A247Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)
Auteurs : Marcus D. Flather [Royaume-Uni] ; Marcelo C. Shibata [Royaume-Uni, Canada] ; Andrew J. S. Coats [Australie] ; Dirk J. Van Veldhuisen [Pays-Bas] ; Aleksandr Parkhomenko [Ukraine] ; Joszef Borbola [Hongrie] ; Alain Cohen-Solal [France] ; Dan Dumitrascu [Roumanie] ; Roberto Ferrari [Italie] ; Philippe Lechat [France] ; Jordi Soler-Soler [Espagne] ; Luigi Tavazzi [Italie] ; Lenka Spinarova [République tchèque] ; Jiri Toman [République tchèque] ; Michael Bo Hm [Allemagne] ; Stefan D. Anker [Allemagne] ; Simon G. Thompson [Royaume-Uni] ; Philip A. Poole-Wilson [Royaume-Uni]Source :
- European Heart Journal [ 0195-668X ] ; 2005-02.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Mortalité, Personne âgée.
English descriptors
- KwdEn :
- Adverse events, Aleksandr parkhomenko, Annual rate, Baseline, Beta adrenergic blockade, Beta blockers, Beta-blocker, Blocker, Blood pressure, Broad range, Cardiac, Cardiology, Cardiovascular, Cardiovascular deaths, Cardiovascular hospital admission, Cardiovascular hospital admissions, Cardiovascular mortality, Carvedilol, Cause death, Cause hospital admissions, Cause hospitalization, Cause mortality, Charite campus berlin, Chronic heart failure, Clinical trials, Cluj napoca, Coll cardiol, Congestive heart failure, Czech republic, Data management, Data safety, Diastolic blood pressure, Diastolic heart failure, Drug intake, Ejection, Ejection fraction, Elderly, Elderly heart failure patients, Elderly patients, Epidemiology, European heart journal, European society, Evaluation unit, Flather, Hazard ratio, Heart failure, Heart rate, Hopital paris, Hospital admission, Hospital admissions, Hungarian institute, Imperial college, Interaction test, Irccs policlinico, Jiri toman, Lancet, Large randomized trials, Last observation, Lenka spinarova, Luigi tavazzi, Maintenance dose, Marcelo shibata, Marcus flather, Masaryk university hospital, Median, Medical research council biostatistics unit, Menarini ricerche, Michael bohm, Mmhg, Monitoring committee, Morbidity studies, Mortality, Mudr, Myocardial infarction, Nebivolol, Nebivolol group, Nebivolol intervention, Placebo, Placebo group, Placebo groups, Previous studies, Previous trials, Previous year, Primary endpoint, Primary outcome, Primary outcomec, Prof, Prognosis, Randomization, Randomized, Randomized trial, Randomized trials, Risk reduction, Roberto ferrari, Royal brompton, Safety concerns, Safety monitoring committee, Salvatore maugeri foundation, Sample size, Science technology, Secondary outcomes, Seniors study, Seniors trial, Steering committee, Study medication, Subgroup, Systolic, Systolic blood pressure, Task force, Titration phase, Unadjusted analysis, Vall barcelona, Vasodilating properties, Ventricular, Ventricular dysfunction, Ventricular ejection fraction, Ventricular function, Younger patients.
- Teeft :
- Adverse events, Aleksandr parkhomenko, Annual rate, Baseline, Beta adrenergic blockade, Beta blockers, Blocker, Blood pressure, Broad range, Cardiac, Cardiology, Cardiovascular, Cardiovascular deaths, Cardiovascular hospital admission, Cardiovascular hospital admissions, Cardiovascular mortality, Carvedilol, Cause death, Cause hospital admissions, Cause hospitalization, Cause mortality, Charite campus berlin, Chronic heart failure, Clinical trials, Cluj napoca, Coll cardiol, Congestive heart failure, Czech republic, Data management, Data safety, Diastolic blood pressure, Diastolic heart failure, Drug intake, Ejection, Ejection fraction, Elderly heart failure patients, Elderly patients, European heart journal, European society, Evaluation unit, Flather, Hazard ratio, Heart failure, Heart rate, Hopital paris, Hospital admission, Hospital admissions, Hungarian institute, Imperial college, Interaction test, Irccs policlinico, Jiri toman, Lancet, Large randomized trials, Last observation, Lenka spinarova, Luigi tavazzi, Maintenance dose, Marcelo shibata, Marcus flather, Masaryk university hospital, Median, Medical research council biostatistics unit, Menarini ricerche, Michael bohm, Mmhg, Monitoring committee, Morbidity studies, Mudr, Myocardial infarction, Nebivolol, Nebivolol group, Nebivolol intervention, Placebo, Placebo group, Placebo groups, Previous studies, Previous trials, Previous year, Primary endpoint, Primary outcome, Primary outcomec, Prof, Randomization, Randomized, Randomized trials, Risk reduction, Roberto ferrari, Royal brompton, Safety concerns, Safety monitoring committee, Salvatore maugeri foundation, Sample size, Science technology, Secondary outcomes, Seniors study, Seniors trial, Steering committee, Study medication, Subgroup, Systolic, Systolic blood pressure, Task force, Titration phase, Unadjusted analysis, Vall barcelona, Vasodilating properties, Ventricular, Ventricular dysfunction, Ventricular ejection fraction, Ventricular function, Younger patients.
Abstract
Aims Large randomized trials have shown that beta-blockers reduce mortality and hospital admissions in patients with heart failure. The effects of beta-blockers in elderly patients with a broad range of left ventricular ejection fraction are uncertain. The SENIORS study was performed to assess effects of the beta-blocker, nebivolol, in patients ≥70 years, regardless of ejection fraction. Methods and results We randomly assigned 2128 patients aged ≥70 years with a history of heart failure (hospital admission for heart failure within the previous year or known ejection fraction ≤35%), 1067 to nebivolol (titrated from 1.25 mg once daily to 10 mg once daily), and 1061 to placebo. The primary outcome was a composite of all cause mortality or cardiovascular hospital admission (time to first event). Analysis was by intention to treat. Mean duration of follow-up was 21 months. Mean age was 76 years (SD 4.7), 37% were female, mean ejection fraction was 36% (with 35% having ejection fraction >35%), and 68% had a prior history of coronary heart disease. The mean maintenance dose of nebivolol was 7.7 mg and of placebo 8.5 mg. The primary outcome occurred in 332 patients (31.1%) on nebivolol compared with 375 (35.3%) on placebo [hazard ratio (HR) 0.86, 95% CI 0.74–0.99; P=0.039]. There was no significant influence of age, gender, or ejection fraction on the effect of nebivolol on the primary outcome. Death (all causes) occurred in 169 (15.8%) on nebivolol and 192 (18.1%) on placebo (HR 0.88, 95% CI 0.71–1.08; P=0.21). Conclusion Nebivolol, a beta-blocker with vasodilating properties, is an effective and well-tolerated treatment for heart failure in the elderly.
Url:
DOI: 10.1093/eurheartj/ehi115
Affiliations:
- Allemagne, Australie, Canada, Espagne, France, Hongrie, Italie, Pays-Bas, Roumanie, Royaume-Uni, République tchèque, Ukraine
- Angleterre, Berlin, Catalogne, Grand Londres, Groningue (province), Hongrie centrale, Moravie, Nouvelle-Galles du Sud, Île-de-France
- Barcelone, Berlin, Brno, Budapest, Groningue, Londres, Paris, Sydney
- Université de Sydney
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000687
- to stream Istex, to step Curation: 000687
- to stream Istex, to step Checkpoint: 001803
- to stream Main, to step Merge: 00AE11
- to stream PascalFrancis, to step Corpus: 004B05
- to stream PascalFrancis, to step Curation: 001598
- to stream PascalFrancis, to step Checkpoint: 004420
- to stream Main, to step Merge: 00B070
- to stream Main, to step Curation: 00A246
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)</title><author><name sortKey="Flather, Marcus D" sort="Flather, Marcus D" uniqKey="Flather M" first="Marcus D." last="Flather">Marcus D. Flather</name></author><author><name sortKey="Shibata, Marcelo C" sort="Shibata, Marcelo C" uniqKey="Shibata M" first="Marcelo C." last="Shibata">Marcelo C. Shibata</name></author><author><name sortKey="Coats, Andrew J S" sort="Coats, Andrew J S" uniqKey="Coats A" first="Andrew J. S." last="Coats">Andrew J. S. Coats</name></author><author><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J." last="Van Veldhuisen">Dirk J. Van Veldhuisen</name></author><author><name sortKey="Parkhomenko, Aleksandr" sort="Parkhomenko, Aleksandr" uniqKey="Parkhomenko A" first="Aleksandr" last="Parkhomenko">Aleksandr Parkhomenko</name></author><author><name sortKey="Borbola, Joszef" sort="Borbola, Joszef" uniqKey="Borbola J" first="Joszef" last="Borbola">Joszef Borbola</name></author><author><name sortKey="Cohen Solal, Alain" sort="Cohen Solal, Alain" uniqKey="Cohen Solal A" first="Alain" last="Cohen-Solal">Alain Cohen-Solal</name></author><author><name sortKey="Dumitrascu, Dan" sort="Dumitrascu, Dan" uniqKey="Dumitrascu D" first="Dan" last="Dumitrascu">Dan Dumitrascu</name></author><author><name sortKey="Ferrari, Roberto" sort="Ferrari, Roberto" uniqKey="Ferrari R" first="Roberto" last="Ferrari">Roberto Ferrari</name></author><author><name sortKey="Lechat, Philippe" sort="Lechat, Philippe" uniqKey="Lechat P" first="Philippe" last="Lechat">Philippe Lechat</name></author><author><name sortKey="Soler Soler, Jordi" sort="Soler Soler, Jordi" uniqKey="Soler Soler J" first="Jordi" last="Soler-Soler">Jordi Soler-Soler</name></author><author><name sortKey="Tavazzi, Luigi" sort="Tavazzi, Luigi" uniqKey="Tavazzi L" first="Luigi" last="Tavazzi">Luigi Tavazzi</name></author><author><name sortKey="Spinarova, Lenka" sort="Spinarova, Lenka" uniqKey="Spinarova L" first="Lenka" last="Spinarova">Lenka Spinarova</name></author><author><name sortKey="Toman, Jiri" sort="Toman, Jiri" uniqKey="Toman J" first="Jiri" last="Toman">Jiri Toman</name></author><author><name sortKey="Bo Hm, Michael" sort="Bo Hm, Michael" uniqKey="Bo Hm M" first="Michael" last="Bo Hm">Michael Bo Hm</name></author><author><name sortKey="Anker, Stefan D" sort="Anker, Stefan D" uniqKey="Anker S" first="Stefan D." last="Anker">Stefan D. Anker</name></author><author><name sortKey="Thompson, Simon G" sort="Thompson, Simon G" uniqKey="Thompson S" first="Simon G." last="Thompson">Simon G. Thompson</name></author><author><name sortKey="Poole Wilson, Philip A" sort="Poole Wilson, Philip A" uniqKey="Poole Wilson P" first="Philip A." last="Poole-Wilson">Philip A. Poole-Wilson</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:233088D5382ECAD4BF8A5104C5D468729CDD526F</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1093/eurheartj/ehi115</idno><idno type="url">https://api.istex.fr/document/233088D5382ECAD4BF8A5104C5D468729CDD526F/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000687</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000687</idno><idno type="wicri:Area/Istex/Curation">000687</idno><idno type="wicri:Area/Istex/Checkpoint">001803</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001803</idno><idno type="wicri:doubleKey">0195-668X:2005:Flather M:randomized:trial:to</idno><idno type="wicri:Area/Main/Merge">00AE11</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:05-0092962</idno><idno type="wicri:Area/PascalFrancis/Corpus">004B05</idno><idno type="wicri:Area/PascalFrancis/Curation">001598</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">004420</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">004420</idno><idno type="wicri:doubleKey">0195-668X:2005:Flather M:randomized:trial:to</idno><idno type="wicri:Area/Main/Merge">00B070</idno><idno type="wicri:Area/Main/Curation">00A246</idno><idno type="wicri:Area/Main/Exploration">00A246</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)</title><author><name sortKey="Flather, Marcus D" sort="Flather, Marcus D" uniqKey="Flather M" first="Marcus D." last="Flather">Marcus D. Flather</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Clinical Trials and Evaluation Unit, Royal Brompton and Harefield NHS Trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Heart and Lung Institute, Imperial College of Science Technology and Medicine, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Shibata, Marcelo C" sort="Shibata, Marcelo C" uniqKey="Shibata M" first="Marcelo C." last="Shibata">Marcelo C. Shibata</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Clinical Trials and Evaluation Unit, Royal Brompton and Harefield NHS Trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Cardiology, University of Alberta, Edmonton</wicri:regionArea><wicri:noRegion>Edmonton</wicri:noRegion></affiliation></author><author><name sortKey="Coats, Andrew J S" sort="Coats, Andrew J S" uniqKey="Coats A" first="Andrew J. S." last="Coats">Andrew J. S. Coats</name><affiliation wicri:level="4"><country xml:lang="fr">Australie</country><wicri:regionArea>Faculty of Medicine, University of Sydney, Sydney 2006</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation><affiliation><wicri:noCountry code="syntax">???</wicri:noCountry></affiliation><affiliation></affiliation><affiliation></affiliation></author><author><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J." last="Van Veldhuisen">Dirk J. Van Veldhuisen</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Cardiology, University Hospital, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Parkhomenko, Aleksandr" sort="Parkhomenko, Aleksandr" uniqKey="Parkhomenko A" first="Aleksandr" last="Parkhomenko">Aleksandr Parkhomenko</name><affiliation wicri:level="1"><country xml:lang="fr">Ukraine</country><wicri:regionArea>Institute of Cardiology, Academy of Science of Ukraine, Kiev</wicri:regionArea><wicri:noRegion>Kiev</wicri:noRegion></affiliation></author><author><name sortKey="Borbola, Joszef" sort="Borbola, Joszef" uniqKey="Borbola J" first="Joszef" last="Borbola">Joszef Borbola</name><affiliation wicri:level="3"><country xml:lang="fr">Hongrie</country><wicri:regionArea>Hungarian Institute of Cardiology, Budapest</wicri:regionArea><placeName><settlement type="city">Budapest</settlement><region nuts="2">Hongrie centrale</region></placeName></affiliation></author><author><name sortKey="Cohen Solal, Alain" sort="Cohen Solal, Alain" uniqKey="Cohen Solal A" first="Alain" last="Cohen-Solal">Alain Cohen-Solal</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service de Cardiologie, Hôpital Beaujon, Clichy</wicri:regionArea><wicri:noRegion>Clichy</wicri:noRegion><wicri:noRegion>Clichy</wicri:noRegion></affiliation></author><author><name sortKey="Dumitrascu, Dan" sort="Dumitrascu, Dan" uniqKey="Dumitrascu D" first="Dan" last="Dumitrascu">Dan Dumitrascu</name><affiliation wicri:level="1"><country xml:lang="fr">Roumanie</country><wicri:regionArea>University of Pharmacy and Medicine, Cluj Napoca</wicri:regionArea><wicri:noRegion>Cluj Napoca</wicri:noRegion></affiliation></author><author><name sortKey="Ferrari, Roberto" sort="Ferrari, Roberto" uniqKey="Ferrari R" first="Roberto" last="Ferrari">Roberto Ferrari</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Cardiology, University of Ferrara, Ferrara</wicri:regionArea><wicri:noRegion>Ferrara</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Cardiovascular Research Centre, Salvatore Maugeri Foundation, IRCCS, Gussago</wicri:regionArea><wicri:noRegion>Gussago</wicri:noRegion></affiliation></author><author><name sortKey="Lechat, Philippe" sort="Lechat, Philippe" uniqKey="Lechat P" first="Philippe" last="Lechat">Philippe Lechat</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie, Hôpital Pitie-Salpetrière, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Soler Soler, Jordi" sort="Soler Soler, Jordi" uniqKey="Soler Soler J" first="Jordi" last="Soler-Soler">Jordi Soler-Soler</name><affiliation wicri:level="3"><country xml:lang="fr">Espagne</country><wicri:regionArea>Cardiology Division, Hospital General Vall d'Hebron, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Tavazzi, Luigi" sort="Tavazzi, Luigi" uniqKey="Tavazzi L" first="Luigi" last="Tavazzi">Luigi Tavazzi</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Cardiology, IRCCS Policlinico San Matteo, Pavia</wicri:regionArea><wicri:noRegion>Pavia</wicri:noRegion></affiliation></author><author><name sortKey="Spinarova, Lenka" sort="Spinarova, Lenka" uniqKey="Spinarova L" first="Lenka" last="Spinarova">Lenka Spinarova</name><affiliation wicri:level="3"><country xml:lang="fr">République tchèque</country><wicri:regionArea>1st Department of Medicine, Masaryk University Hospital, Brno</wicri:regionArea><placeName><settlement type="city">Brno</settlement><region>Moravie</region></placeName></affiliation></author><author><name sortKey="Toman, Jiri" sort="Toman, Jiri" uniqKey="Toman J" first="Jiri" last="Toman">Jiri Toman</name><affiliation wicri:level="3"><country xml:lang="fr">République tchèque</country><wicri:regionArea>1st Department of Medicine, Masaryk University Hospital, Brno</wicri:regionArea><placeName><settlement type="city">Brno</settlement><region>Moravie</region></placeName></affiliation></author><author><name sortKey="Bo Hm, Michael" sort="Bo Hm, Michael" uniqKey="Bo Hm M" first="Michael" last="Bo Hm">Michael Bo Hm</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Universitätskliniken des Saarlandes, Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Homburg/Saar</wicri:regionArea><wicri:noRegion>Homburg/Saar</wicri:noRegion><wicri:noRegion>Homburg/Saar</wicri:noRegion></affiliation></author><author><name sortKey="Anker, Stefan D" sort="Anker, Stefan D" uniqKey="Anker S" first="Stefan D." last="Anker">Stefan D. Anker</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Cardiology, Charité Campus Virchow-Klinikum, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Thompson, Simon G" sort="Thompson, Simon G" uniqKey="Thompson S" first="Simon G." last="Thompson">Simon G. Thompson</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Medical Research Council Biostatistics Unit, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author><author><name sortKey="Poole Wilson, Philip A" sort="Poole Wilson, Philip A" uniqKey="Poole Wilson P" first="Philip A." last="Poole-Wilson">Philip A. Poole-Wilson</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Heart and Lung Institute, Imperial College of Science Technology and Medicine, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">European Heart Journal</title><title level="j" type="abbrev">Eur Heart J</title><idno type="ISSN">0195-668X</idno><idno type="eISSN">1522-9645</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2005-02">2005-02</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="215">215</biblScope><biblScope unit="page" to="225">225</biblScope></imprint><idno type="ISSN">0195-668X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0195-668X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adverse events</term><term>Aleksandr parkhomenko</term><term>Annual rate</term><term>Baseline</term><term>Beta adrenergic blockade</term><term>Beta blockers</term><term>Beta-blocker</term><term>Blocker</term><term>Blood pressure</term><term>Broad range</term><term>Cardiac</term><term>Cardiology</term><term>Cardiovascular</term><term>Cardiovascular deaths</term><term>Cardiovascular hospital admission</term><term>Cardiovascular hospital admissions</term><term>Cardiovascular mortality</term><term>Carvedilol</term><term>Cause death</term><term>Cause hospital admissions</term><term>Cause hospitalization</term><term>Cause mortality</term><term>Charite campus berlin</term><term>Chronic heart failure</term><term>Clinical trials</term><term>Cluj napoca</term><term>Coll cardiol</term><term>Congestive heart failure</term><term>Czech republic</term><term>Data management</term><term>Data safety</term><term>Diastolic blood pressure</term><term>Diastolic heart failure</term><term>Drug intake</term><term>Ejection</term><term>Ejection fraction</term><term>Elderly</term><term>Elderly heart failure patients</term><term>Elderly patients</term><term>Epidemiology</term><term>European heart journal</term><term>European society</term><term>Evaluation unit</term><term>Flather</term><term>Hazard ratio</term><term>Heart failure</term><term>Heart rate</term><term>Hopital paris</term><term>Hospital admission</term><term>Hospital admissions</term><term>Hungarian institute</term><term>Imperial college</term><term>Interaction test</term><term>Irccs policlinico</term><term>Jiri toman</term><term>Lancet</term><term>Large randomized trials</term><term>Last observation</term><term>Lenka spinarova</term><term>Luigi tavazzi</term><term>Maintenance dose</term><term>Marcelo shibata</term><term>Marcus flather</term><term>Masaryk university hospital</term><term>Median</term><term>Medical research council biostatistics unit</term><term>Menarini ricerche</term><term>Michael bohm</term><term>Mmhg</term><term>Monitoring committee</term><term>Morbidity studies</term><term>Mortality</term><term>Mudr</term><term>Myocardial infarction</term><term>Nebivolol</term><term>Nebivolol group</term><term>Nebivolol intervention</term><term>Placebo</term><term>Placebo group</term><term>Placebo groups</term><term>Previous studies</term><term>Previous trials</term><term>Previous year</term><term>Primary endpoint</term><term>Primary outcome</term><term>Primary outcomec</term><term>Prof</term><term>Prognosis</term><term>Randomization</term><term>Randomized</term><term>Randomized trial</term><term>Randomized trials</term><term>Risk reduction</term><term>Roberto ferrari</term><term>Royal brompton</term><term>Safety concerns</term><term>Safety monitoring committee</term><term>Salvatore maugeri foundation</term><term>Sample size</term><term>Science technology</term><term>Secondary outcomes</term><term>Seniors study</term><term>Seniors trial</term><term>Steering committee</term><term>Study medication</term><term>Subgroup</term><term>Systolic</term><term>Systolic blood pressure</term><term>Task force</term><term>Titration phase</term><term>Unadjusted analysis</term><term>Vall barcelona</term><term>Vasodilating properties</term><term>Ventricular</term><term>Ventricular dysfunction</term><term>Ventricular ejection fraction</term><term>Ventricular function</term><term>Younger patients</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Admission hôpital</term><term>Epidémiologie</term><term>Insuffisance cardiaque</term><term>Mortalité</term><term>Personne âgée</term><term>Pronostic</term><term>Randomisation</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Adverse events</term><term>Aleksandr parkhomenko</term><term>Annual rate</term><term>Baseline</term><term>Beta adrenergic blockade</term><term>Beta blockers</term><term>Blocker</term><term>Blood pressure</term><term>Broad range</term><term>Cardiac</term><term>Cardiology</term><term>Cardiovascular</term><term>Cardiovascular deaths</term><term>Cardiovascular hospital admission</term><term>Cardiovascular hospital admissions</term><term>Cardiovascular mortality</term><term>Carvedilol</term><term>Cause death</term><term>Cause hospital admissions</term><term>Cause hospitalization</term><term>Cause mortality</term><term>Charite campus berlin</term><term>Chronic heart failure</term><term>Clinical trials</term><term>Cluj napoca</term><term>Coll cardiol</term><term>Congestive heart failure</term><term>Czech republic</term><term>Data management</term><term>Data safety</term><term>Diastolic blood pressure</term><term>Diastolic heart failure</term><term>Drug intake</term><term>Ejection</term><term>Ejection fraction</term><term>Elderly heart failure patients</term><term>Elderly patients</term><term>European heart journal</term><term>European society</term><term>Evaluation unit</term><term>Flather</term><term>Hazard ratio</term><term>Heart failure</term><term>Heart rate</term><term>Hopital paris</term><term>Hospital admission</term><term>Hospital admissions</term><term>Hungarian institute</term><term>Imperial college</term><term>Interaction test</term><term>Irccs policlinico</term><term>Jiri toman</term><term>Lancet</term><term>Large randomized trials</term><term>Last observation</term><term>Lenka spinarova</term><term>Luigi tavazzi</term><term>Maintenance dose</term><term>Marcelo shibata</term><term>Marcus flather</term><term>Masaryk university hospital</term><term>Median</term><term>Medical research council biostatistics unit</term><term>Menarini ricerche</term><term>Michael bohm</term><term>Mmhg</term><term>Monitoring committee</term><term>Morbidity studies</term><term>Mudr</term><term>Myocardial infarction</term><term>Nebivolol</term><term>Nebivolol group</term><term>Nebivolol intervention</term><term>Placebo</term><term>Placebo group</term><term>Placebo groups</term><term>Previous studies</term><term>Previous trials</term><term>Previous year</term><term>Primary endpoint</term><term>Primary outcome</term><term>Primary outcomec</term><term>Prof</term><term>Randomization</term><term>Randomized</term><term>Randomized trials</term><term>Risk reduction</term><term>Roberto ferrari</term><term>Royal brompton</term><term>Safety concerns</term><term>Safety monitoring committee</term><term>Salvatore maugeri foundation</term><term>Sample size</term><term>Science technology</term><term>Secondary outcomes</term><term>Seniors study</term><term>Seniors trial</term><term>Steering committee</term><term>Study medication</term><term>Subgroup</term><term>Systolic</term><term>Systolic blood pressure</term><term>Task force</term><term>Titration phase</term><term>Unadjusted analysis</term><term>Vall barcelona</term><term>Vasodilating properties</term><term>Ventricular</term><term>Ventricular dysfunction</term><term>Ventricular ejection fraction</term><term>Ventricular function</term><term>Younger patients</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Mortalité</term><term>Personne âgée</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Aims Large randomized trials have shown that beta-blockers reduce mortality and hospital admissions in patients with heart failure. The effects of beta-blockers in elderly patients with a broad range of left ventricular ejection fraction are uncertain. The SENIORS study was performed to assess effects of the beta-blocker, nebivolol, in patients ≥70 years, regardless of ejection fraction. Methods and results We randomly assigned 2128 patients aged ≥70 years with a history of heart failure (hospital admission for heart failure within the previous year or known ejection fraction ≤35%), 1067 to nebivolol (titrated from 1.25 mg once daily to 10 mg once daily), and 1061 to placebo. The primary outcome was a composite of all cause mortality or cardiovascular hospital admission (time to first event). Analysis was by intention to treat. Mean duration of follow-up was 21 months. Mean age was 76 years (SD 4.7), 37% were female, mean ejection fraction was 36% (with 35% having ejection fraction >35%), and 68% had a prior history of coronary heart disease. The mean maintenance dose of nebivolol was 7.7 mg and of placebo 8.5 mg. The primary outcome occurred in 332 patients (31.1%) on nebivolol compared with 375 (35.3%) on placebo [hazard ratio (HR) 0.86, 95% CI 0.74–0.99; P=0.039]. There was no significant influence of age, gender, or ejection fraction on the effect of nebivolol on the primary outcome. Death (all causes) occurred in 169 (15.8%) on nebivolol and 192 (18.1%) on placebo (HR 0.88, 95% CI 0.71–1.08; P=0.21). Conclusion Nebivolol, a beta-blocker with vasodilating properties, is an effective and well-tolerated treatment for heart failure in the elderly.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Canada</li><li>Espagne</li><li>France</li><li>Hongrie</li><li>Italie</li><li>Pays-Bas</li><li>Roumanie</li><li>Royaume-Uni</li><li>République tchèque</li><li>Ukraine</li></country><region><li>Angleterre</li><li>Berlin</li><li>Catalogne</li><li>Grand Londres</li><li>Groningue (province)</li><li>Hongrie centrale</li><li>Moravie</li><li>Nouvelle-Galles du Sud</li><li>Île-de-France</li></region><settlement><li>Barcelone</li><li>Berlin</li><li>Brno</li><li>Budapest</li><li>Groningue</li><li>Londres</li><li>Paris</li><li>Sydney</li></settlement><orgName><li>Université de Sydney</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Flather, Marcus D" sort="Flather, Marcus D" uniqKey="Flather M" first="Marcus D." last="Flather">Marcus D. Flather</name></region><name sortKey="Flather, Marcus D" sort="Flather, Marcus D" uniqKey="Flather M" first="Marcus D." last="Flather">Marcus D. Flather</name><name sortKey="Poole Wilson, Philip A" sort="Poole Wilson, Philip A" uniqKey="Poole Wilson P" first="Philip A." last="Poole-Wilson">Philip A. Poole-Wilson</name><name sortKey="Shibata, Marcelo C" sort="Shibata, Marcelo C" uniqKey="Shibata M" first="Marcelo C." last="Shibata">Marcelo C. Shibata</name><name sortKey="Thompson, Simon G" sort="Thompson, Simon G" uniqKey="Thompson S" first="Simon G." last="Thompson">Simon G. Thompson</name></country><country name="Canada"><noRegion><name sortKey="Shibata, Marcelo C" sort="Shibata, Marcelo C" uniqKey="Shibata M" first="Marcelo C." last="Shibata">Marcelo C. Shibata</name></noRegion></country><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Coats, Andrew J S" sort="Coats, Andrew J S" uniqKey="Coats A" first="Andrew J. S." last="Coats">Andrew J. S. Coats</name></region></country><country name="Pays-Bas"><region name="Groningue (province)"><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J." last="Van Veldhuisen">Dirk J. Van Veldhuisen</name></region></country><country name="Ukraine"><noRegion><name sortKey="Parkhomenko, Aleksandr" sort="Parkhomenko, Aleksandr" uniqKey="Parkhomenko A" first="Aleksandr" last="Parkhomenko">Aleksandr Parkhomenko</name></noRegion></country><country name="Hongrie"><region name="Hongrie centrale"><name sortKey="Borbola, Joszef" sort="Borbola, Joszef" uniqKey="Borbola J" first="Joszef" last="Borbola">Joszef Borbola</name></region></country><country name="France"><noRegion><name sortKey="Cohen Solal, Alain" sort="Cohen Solal, Alain" uniqKey="Cohen Solal A" first="Alain" last="Cohen-Solal">Alain Cohen-Solal</name></noRegion><name sortKey="Lechat, Philippe" sort="Lechat, Philippe" uniqKey="Lechat P" first="Philippe" last="Lechat">Philippe Lechat</name></country><country name="Roumanie"><noRegion><name sortKey="Dumitrascu, Dan" sort="Dumitrascu, Dan" uniqKey="Dumitrascu D" first="Dan" last="Dumitrascu">Dan Dumitrascu</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Ferrari, Roberto" sort="Ferrari, Roberto" uniqKey="Ferrari R" first="Roberto" last="Ferrari">Roberto Ferrari</name></noRegion><name sortKey="Ferrari, Roberto" sort="Ferrari, Roberto" uniqKey="Ferrari R" first="Roberto" last="Ferrari">Roberto Ferrari</name><name sortKey="Tavazzi, Luigi" sort="Tavazzi, Luigi" uniqKey="Tavazzi L" first="Luigi" last="Tavazzi">Luigi Tavazzi</name></country><country name="Espagne"><region name="Catalogne"><name sortKey="Soler Soler, Jordi" sort="Soler Soler, Jordi" uniqKey="Soler Soler J" first="Jordi" last="Soler-Soler">Jordi Soler-Soler</name></region></country><country name="République tchèque"><region name="Moravie"><name sortKey="Spinarova, Lenka" sort="Spinarova, Lenka" uniqKey="Spinarova L" first="Lenka" last="Spinarova">Lenka Spinarova</name></region><name sortKey="Toman, Jiri" sort="Toman, Jiri" uniqKey="Toman J" first="Jiri" last="Toman">Jiri Toman</name></country><country name="Allemagne"><noRegion><name sortKey="Bo Hm, Michael" sort="Bo Hm, Michael" uniqKey="Bo Hm M" first="Michael" last="Bo Hm">Michael Bo Hm</name></noRegion><name sortKey="Anker, Stefan D" sort="Anker, Stefan D" uniqKey="Anker S" first="Stefan D." last="Anker">Stefan D. Anker</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00A246 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00A246 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:233088D5382ECAD4BF8A5104C5D468729CDD526F
|texte= Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)
}}
| This area was generated with Dilib version V0.6.33. |  |